Call Options

2 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2023

Nov 14, 2023

SELL
$14.09 - $19.87 $2.82 Million - $3.97 Million
-200,000 Reduced 50.0%
200,000 $3.17 Million
Q2 2023

Aug 14, 2023

BUY
$3.75 - $20.05 $1.5 Million - $8.02 Million
400,000 New
400,000 $7.55 Million

Others Institutions Holding IMGN

About ImmunoGen, Inc.


  • Ticker IMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 220,712,992
  • Description
  • ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...
More about IMGN
Track This Portfolio

Track Lmr Partners LLP Portfolio

Follow Lmr Partners LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lmr Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Lmr Partners LLP with notifications on news.